Keeping Track: Disappointment For Mesoblast And Aquestive; Opdivo/Yervoy Add Mesothelioma Claim; Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

A new mesothelioma indication for Bristol Myers Squibb Company’s Opdivo and Yervoy combination capped a week otherwise notable for two complete response letters – for Mesoblast’s remestemcel-L and Aquestive’s Libervant (buccal diazepam) – and a host of pediatric approvals from the US Food and Drug Administration.

The FDA’s biggest approval decisions last week came down against approval, with complete response letters announced for Mesoblast Limited’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers